Investor Relations

Bringing Science to Society™

Company Overview

In the first quarter of 2022, we announced our transformation from Recro to Societal™ CDMO. With this change, we are committed to helping our partners expedite the delivery of life-changing pharmaceuticals to patients.

Societal CDMO (NASDAQ: SCTL) is a bi-coastal contract development and manufacturing organization (CDMO) with capabilities spanning pre-Investigational New Drug (IND) development to commercial manufacturing and packaging for a wide range of therapeutic dosage forms with a primary focus in the area of small molecules. With an expertise in solving complex manufacturing problems, Societal CDMO is a leading CDMO providing therapeutic development, end-to-end regulatory support, clinical and commercial manufacturing, aseptic fill/finish, lyophilization, packaging, and logistics services to the global pharmaceutical market.

In addition to our experience in handling DEA controlled substances and developing and manufacturing modified-release dosage forms, Societal CDMO has the expertise to deliver on our clients’ pharmaceutical development and manufacturing projects, regardless of complexity level. We do all of this in our best-in-class facilities, totaling 145,000 square feet, in Gainesville, Georgia, and San Diego, California.

Stock Snapshot

IR Contacts

Company

Societal CDMO
1 E. Uwchlan Ave
Suite 112
Exton, PA 19341
T: 770-531-8365
investorrelations@societalcdmo.com

Investor Relations

Vida Strategic Partners
Stephanie Diaz
T: 415-675-7401
sdiaz@vidasp.com

Market Data copyright © 2022 QuoteMedia. Data delayed 15 minutes unless otherwise indicated (view delay times for all exchanges). RT=Real-Time, EOD=End of Day, PD=Previous Day. Market Data powered by QuoteMedia. Terms of Use.